PRESS RELEASE
News
-
-
PRESS RELEASE
New to The Street Announces 12-Month National Media Partnership with Stardust Power (NASDAQ: SDST)
Stardust Power partners with New to The Street for 12-month national media collaboration. The partnership includes TV interviews, media placements, TV commercials, and billboard campaigns to showcase America's energy leadership efforts -
PRESS RELEASE
Bird River Announces Closing of 4th Tranche of Common Share Financing For Gross Proceeds of Approximately $709,299 and Early Warning Disclosure
Bird River Resources Inc. closed a fourth tranche of private placement financing, issuing 8,866,239 Common Shares at $0.08 per share, with aggregate gross proceeds of $709,299.12 for general corporate purposes -
-
PRESS RELEASE
Eightco Holdings Inc. ($ORBS) Digital Asset Treasury Launches "Chairman's Message" Video Series
Eightco Holdings Inc. launches 'Chairman's Message' video series to support the 'Power of Eight' initiative, focusing on Worldcoin (WLD) tokens and Proof-of-Human verification for the AI era. The company aims to acquire 800M WLD tokens with a $10 projection, potentially valuing at $8B -
PRESS RELEASE
Disclosure of total number of voting rights and number of shares in the capital at September 30, 2025
L'Oréal, a French limited company with a registered capital of 106,640,982.60 euros, discloses its voting rights and shares. The leading beauty player emphasizes sustainability and innovation -
-
PRESS RELEASE
2025 International MICE Summit (IMS) to convene global leaders as Vision 2030 powers Saudi Arabia's rise as a global hub for business events
Saudi Arabia to host International MICE Summit (IMS25) bringing over 2,000 global leaders, reinforcing its position as a major business events destination under Vision 2030 -
PRESS RELEASE
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Icotrokinra meets primary clinical endpoints in Phase 2b study for ulcerative colitis treatment, showing promising results at Week 12. Phase 3 trials expected to start in Q4 2025 -
